# Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

> **NCT00002482** · PHASE1,PHASE2 · UNKNOWN · sponsor: **St. Vincent Medical Center - Los Angeles**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** antibody therapy
- **BIOLOGICAL:** biological therapy
- **BIOLOGICAL:** muromonab-CD3
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00002482
- **Lead sponsor:** St. Vincent Medical Center - Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1991-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002482, "Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00002482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*